Prevention of Influenza in Children

Infectious Disease Clinics of North America

Volumn 29, Issue 4, 2015, Pages 597-615

  Livingston, Robyn A ^a,b   Bernstein, Henry H ^c  

^a CHILDREN S MERCY KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antivirals; Chemoprophylaxis; Influenza; Treatment; Vaccine

Indexed keywords

ADAMANTANE; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BACTERIAL PNEUMONIA; BRAIN DISEASE; CHEMOPROPHYLAXIS; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; DRUG EFFICACY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MEDICAL HISTORY; PHYSICAL EXAMINATION; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; RAPID TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; REYE SYNDROME; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS CULTURE; VIRUS PNEUMONIA; VIRUS TRANSMISSION; ADOLESCENT; ADULT; INFANT; INFLUENZA, HUMAN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84947719554     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.07.008     Document Type: Review

References (44)

1. Neuzil K.M., Zhu Y., Griffin M.R., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185:147-152.
2. Glezen W.P. Emerging infections: pandemic influenza. Epidemiol Rev 1996, 18:64-76.
3. Longini I.M., Koopman J.S., Monto A.S., et al. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982, 115:736-751.
4. 2013-2014 influenza season. Centers for Disease Control and Prevention. 2014. Available at: . Accessed April 21, 2015. http://www.cdc.gov/flu/pastseasons/1314season.htm.
5. Wong K.K., Jain S., Blanton L., et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics 2013, 132:796-804.
6. Peltola V., Ziegler T., Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003, 36:299-305.
7. Meibalane R., Sedmak G.V., Sasidharan P., et al. Outbreak of influenza in a neonatal intensive care unit. J Pediatr 1977, 91:974-976.
8. Hu J.J., Kao C.L., Lee P.I., et al. Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect 2004, 37:95-98.
9. Lau L.L., Cowling B.J., Fang V.J., et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis 2010, 201:1509-1516.
10. Klimov A.I., Rocha E., Hayden F.G., et al. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995, 172:1352-1355.
11. Frank A.L., Taber L.H., Wells C.R., et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981, 144:433-441.
12. Brill S.J., Gilfillan R.F. Acute parotitis associated with influenza type A: a report of twelve cases. N Engl J Med 1977, 296:1391-1392.
13. Krilov L.R., Swenson P. Acute parotitis associated with influenza A infection. J Infect Dis 1985, 152:853.
14. Overview of influenza surveillance in the United States. Centers for Disease Control and Prevention. 2015. Available at: . Accessed April 25, 2015. http://www.cdc.gov/flu/weekly/overview.htm.
15. Chartrand C., Leeflang M.M., Minion J., et al. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012, 156:500-511.
16. Dunn J.J., Woolstenhulme R.D., Langer J., et al. Sensitivity of respiratory virus culture when screening with R-mix fresh cells. J Clin Microbiol 2004, 42:79-82.
17. WHO Recommendations on the use of rapid testing for influenza diagnosis. World Health Organization. 2005. Available at: . Accessed May 10, 2015. http://www.who.int/influenza/resources/documents/RapidTestInfluenza_WebVersion.pdf?ua=1.
18. Ünal S., Gökce M., Aytac-Elmas S., et al. Hematological consequences of pandemic influenza H1N1 infection: a single center experience. Turk J Pediatr 2010, 52:570-575.
19. Yingying C. Abnormal liver chemistry in patients with influenza A H1N1. Liver Int 2011, 31:902.
20. Antiviral drugs for seasonal influenza: additional links and resources. Centers for Disease Control and Prevention. 2015. Available at: . Accessed May 27, 2015. http://www.cdc.gov/flu/professionals/antivirals/links.htm.
21. Highlights of prescribing information: Rapivab (peramivir injection). Food and Drug Administration. 2014. Available at: . Accessed May 27, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf.
22. Fiore A.E., Fry A., Shay D., Centers for Disease Control and Prevention, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ 2011, 60:1-24.
23. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20:127-133.
24. Heinonen S., Silvennoinen H., Lehtinen P., et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010, 51:887-894.
25. Hedrick J.A., Barzilai A., Behre U., et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000, 19(5):410-417.
26. Influenza antiviral medications: summary for clinicians. Centers for Disease Control and Prevention Web Site. 2015. Available at: . Accessed July 1, 2015. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
27. Iwane M.K., Edwards K.M., Szilagyi P.G., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004, 113:1758-1764.
28. Metersky M.L., Masterton R.G., Lode H., et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012, 16:e321-e331. [review].
29. Surtees R., DeSousa C. Influenza virus associated encephalopathy. Arch Dis Child 2006, 91:455-456.
30. Centers for Disease Control and Prevention Reye syndrome surveillance-United States, 1989. MMWR Morb Mortal Wkly Rep 1991, 40:88-90.
31. Belay E.D., Bresee J.S., Holman R.C., et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999, 340:1377-1382.
32. Highlights of prescribing information: Flumist quadrivalent. Medimmune. Available at: . Accessed July 5, 2015. http://www.medimmune.com/docs/default-source/default-document-library/product-and-patient-information-for-flumist-quadrivalent.pdf.
33. FLUCELVAX - Novartis Vaccines and Diagnostics, Inc 1.14.1.3 US Package Insert April 2015. Food and Drug Administration. Available at: . Accessed July 5, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM329134.pdf.
34. Protein Sciences Corporation Influenza Vaccine Package Insert BLA STN 125285. Available at: . Accessed July 5, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf.
35. Neuzil K.M., Dupont W.D., Wright P.F., et al. Efficacy of inactivated and cold-adapted vaccines. against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001, 20:733-740.
36. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998, 338:1405-1412.
37. Belshe R.B., Edwards K.M., Vesikari T., CAIV-T Comparative Efficacy Study Group, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
38. Centers for Disease Control and Prevention Update: influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep 2015, 64:206-212.
39. Hayden F.G., Gubareva L.V., Monto A.S., Zanamivir Family Study Group, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000, 343:1282-1289.
40. Welliver R., Monto A.S., Carewicz O., Oseltamivir Post Exposure Prophylaxis Investigator Group, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001, 285:748-754.
41. Monto A.S., Pichichero M.E., Blanckenberg S.J., et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002, 186(11):1582-1588.
42. Hayden F.G., Atmar R.L., Schilling M., et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999, 341:1336-1343.
43. Monto A.S., Robinson D.P., Herlocher M.L., et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999, 282:31-35.
44. Khazeni N., Bravata D.M., Holty J.E., et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009, 151:464-473.